BIOMARIN PHARMACEUTICAL INC

BMRNSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1048477

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$2.4B	$2.1B	$1.8B	$1.9B	$1.7B
Cost of Revenue	$532.1M	$503.0M	$470.5M	$524.3M	$359.5M
Research and Development Expense	$746.8M	$649.6M	$628.8M	$628.1M	$715.0M
Selling, General and Administrative Expense	$892.4M	$823.2M	$759.4M	$737.7M	$680.9M
Operating Income (Loss)	$185.8M	$161.0M	-$82.3M	-$43.4M	-$100.5M
Interest Expense	—	—	$15.3M	$29.3M	$23.5M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$188.6M	$149.6M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$7.0B	$6.8B	$6.4B	$6.0B	$5.8B
Assets, Current	$3.2B	$3.0B	$2.8B	$2.3B	$2.3B
Cash and Cash Equivalents, at Carrying Value	$942.8M	$755.1M	$724.5M	$587.3M	$649.2M
Accounts Receivable, after Allowance for Credit Loss, Current	$660.5M	$633.7M	$461.3M	$373.4M	$448.4M
Inventory, Net	$1.2B	$1.1B	$894.1M	$776.7M	$698.5M
Liabilities	$1.3B	$1.9B	$1.8B	$1.7B	$1.7B
Liabilities, Current	$607.0M	$1.2B	$588.9M	$546.5M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	$159.3M	$175.9M	$304.5M	$85.4M	$48.3M
Net Cash Provided by (Used in) Investing Activities	-$111.2M	-$20.0M	-$366.3M	-$53.6M	-$31.0M
Net Cash Provided by (Used in) Financing Activities	-$18.7M	-$18.6M	-$48.0K	$181.1M	-$74.7M
Payments to Acquire Property, Plant, and Equipment	$96.7M	$121.0M	$95.6M	$114.3M	$145.0M
Payments for Repurchase of Common Stock	—	—	—	$50.0M	$0.00

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)